Merit Medical Systems to Announce Fourth Quarter and Year End 2021 Results on February 24, 2022

Ads

You May Also Like

Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech

PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech ...

ContraFect to Present at 10th Annual Biotech Showcase

YONKERS, N.Y., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

22 Winners Receive the 2018 MAP Award for High Performance in Revenue Cycle

Westchester, Illinois, May 21, 2018 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) ...